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The subcellular fractions containing protein kinases capable of phosphorylating basic fibroblast growth factor (FGF-2) are unknown, but having 
previously characterized one that is associated with the plasma membrane [1991, Mol. Endocrinol. 5, 1003310121 we evaluated the catalytic 
properties of another in the nucleus. The reaction is time (linear up to 15 min), enzyme (2,000-25,000 nuclei/ml), and substrate (X, 0.18 ,uM) 
dependent, and the targets serine. DNase pretreatment of nuclei decreases the incorporation of phosphate into FGF-2 by 50% and the reaction. 
It is also inhibited by heparin (EC, 1 pug/ml) and spermidine (EC,, 3 PM). Calcium and CAMP have no effect. We conclude that the kinase is distinct 
from PKA, and PKC, and suggest hat changes in glycosaminoglycan and polyamine concentrations during the cell cycle may modulate FGF-2 
phosphorylation in the nucleus, or as it is translocated to the nucleus. 
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1. INTRODUCTION detectable in the nuclei of cells (Balb-C 3T3 fibroblasts) 
that do not synthesize the growth factor. 
Basic fibroblast growth factor (FGF-2) is a potent 
mitogen and morphogen for many diverse cell types 
[1,2]. In cell culture, it is synthesized by numerous cells, 
including endothelial cells [3,4], granulosa cells [5], and 
various types of tumor cells [6-81. Over 95% of the 
growth factor produced by these cells, however, remains 
cell associated, since the mature protein lacks a signal 
sequence to mediate secretion [9]. Thus, although basic 
FGF appears to be exported to the cell surface [lo] and 
sometimes deposited into the extracellular matrix [4,11], 
the mechanism for its translocation to and from the 
matrix is unknown. 
2. MATERIALS AND METHODS 
2.1. Materials 
CAMP, and PK-I (a heat- and acid-stable inhibitor of CAMP-de- 
pendent protein kinase), spermidine, heparin and DNase were pur- 
chased from Sigma. [y-“P]ATP (3,000 Ci/mol) was from ICN Radio- 
chemicals (Irvine, CA). Reagents for polyacrylamide lectrophoresis 
(PAGE) were obtained from Bio-Rad. Recombinant human FGF-2 
was a generous gift of Dr. Paolo Sarmientos, Farmitalia Carlo Erba, 
Milano, Italy and the antiserum to FGF-2 has been described else- 
where [21]. 
2.2. Cell cultures and immunohbtochemistry 
Attempts to understand the regulation of FGF-2 
have been complicated by recent observations howing 
its localization in the cytoplasm and nucleus of numer- 
ous cell types [10,12-151. Because FGF-2 can be 
phosphorylated [16,17], we have proposed this post- 
translational change might regulate its potential parac- 
tine, autocrine, and even intracrine activities [17,18]. 
The phosphorylation and dephosphorylation of pro- 
teins has long been recognized as an important regula- 
tory mechanism of cellular function [19,20]. Protein ki- 
nases exist in a variety of enzymatic forms with distinct 
subcellular distributions and various substrate specifici- 
ties. In the study here, we describe the presence of a 
nuclear, serine-specific FGF-2 kinase which is detecta- 
ble in the nuclei of a cell type that synthesizes FGF-2, 
SK-Hep-1 cells. In contrast, this activity is not readily 
Human hepatoma cells (SK-Hep-1) and Balb-C 3T3 fibroblasts 
were obtained from the ATIC repository, grown as monolayers in 
DME/MEM containing Earle’s salts supplemented with 10% (v/v) calf 
serum (Flow Laboratories, Irvine) and kept in humidified air/CO* 
(95:5; 37°C) atmosphere. The cells were prepared for immunohisto- 
chemistry as described by Florkiewicz et al. [lo]. Specificity of staining 
was determined using a preparation of antibody whose anti-FGF IgG 
had been preadsorbed to an FGF-2 affinity column. 
2.3. Preparation of puriJied nuclei 
*Corresponding author. Fax: (1) (619) 457 5534. 
The technique used to prepare nuclei was developed from that 
described elsewhere [28]. SK-Hep-1 cells were grown in 10 cm dishes, 
and 30 dishes were routinely used for the preparation of nuclei. The 
cells were washed 3 times with cold phosphate-buffered saline (PBS), 
scraped in 50 ml PBS, and centrifuged at 3,000 rpm. The cell pellet was 
homogenized in 10 ml of a HSKM buffer (PH 7.4) that consists of 
HEPES (25 mM), 0.25 M sucrose, 25 mM KCl, 5 mM MgCI,, 0.5% 
Triton X-100 and protease inhibitors (50 &ml leupeptin, 1 &ml 
aprotinin, 1 mM EDTA, and 10 mg/ml pepstatin). The cell homoge- 
nate was incubated at 4°C for 15 min and centrifuged for 5 min at 
3,000 rpm. The pellet was gently resuspended with a Teflon pestle and 
rinsed 3 times with 5 ml of HSKM buffer (without Triton). The final 
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pellet containing purified nuclei was used in the kinase assay or stored 
at -8W’C. The original supematant was further centrifuged at 
125,000 x g for 45 min to obtain plasma membrane, and the supema- 
tant was considered the cytosolic fraction. Balb-C 3T3 cells were 
processed in a similar fashion to obtain plasma membranes, cytosol, 
and nuclei. 
2.4. Extractions and Western blotting 
Nuclei were extracted in a solution of 1% NP-40,0.5% deoxycho- 
late, 1 mM PMSF, 1 mM EGTA, 1 &ml aprotinin, 1 &/ml leupeptin, 
1 &ml pepstatin A, 2 M NaCl in 2 mM Tris-Cl, pH 7.4, as described 
by Florkiewicz and Sommer [22]. The extract was centrifuged and the 
supematant was either analyzed directly or diluted to a conductivity 
~0.2 M NaCl. In these latter samples, an aliquot (50 ~1) of heparin- 
Sepharose was added to the solution and ~cubated at 4°C. Tbii 
solution was ~nt~f~g~ the hepa~n~ph~o~ beads washed with 
0.6 M NaCl, and the proteins bound were solubilized with Laemmli’s 
sample btier 1231 and loaded onto a 15% ~~larni~O.l% bis- 
ac~lamide gels and el~tropbor~. FGF-2 was visualized by West- 
em blotting using an antibody to FGF-2 as described 1241. 
2.5. Phosphorylation amays 
The indicated concentrations of nuclei were incubated with FGF-2 
or the indicated substrates in a fmal volume of 40#. The reaction was 
started by the addition of a reactive solution containing [r-“P$KTP 
(5 PM, I @i/assay) and 5 mM MgCl,. At the end of the incubation, 
10 ~1 of a 5x Laemmli loading b&er was added to stop the reaction. 
The samples were boiled and phospho~lated proteins were analyzed 
by autoradiography after SDS-PAGE. 
Phospho~l~t~ peptides and proteins were prepared for 
phosphoamino acid analyses as described by Cooper et al. [25]. After 
extraction from the dried gel, the phosphoproteins were hydrolyzed 
in 6 N HCl for 90 min at IlO’C. The phosphoamino acids were 
separated by high voltage electrophoresis on c&dose plates at pH 1.9 
and pH 3.5, and the separation visualized by autoradiography. 
3. RESULTS 
3.1” Distribution of FGF-2 in SK-Hep-I cells 
As shown in Fig. lA, an ~unoreactive FGF-2 (ir- 
FGF-2) is associated with the cell surface when the cells 
are not permeabilized. Under permeabilizing condi- 
tions, most of the staining is found in the nucleus (Fig. 
1B). This localization is not exclusive, as there is faint, 
but significant, staining in the cytoplasm. Immunoelec- 
tron microscopy shows this cytoplasmic staining in the 
perinuclear region of SK-Hep-1 cells (not shown). 
In an effort to identify the molecular forms of the 
ir-FGF-2 in the nuclei, nuclear proteins were extracted 
and processed for Western blotting. As shown in Fig. 
lC, the antibody to FGF-2 detects the 18, 22, and 24 
kDa molecular forms of FGF-2 [22] which bind to im- 
mobilized heparin. 
3.2. Endogenous protein kinases in SK-Hep-1 cells 
The subcellular fractions from SK-Hep-I cells were 
prepared as described in section 2, used as potential 
sources of protein kinases and tested for their ability to 
phosphorylate FGF-2. Briefly, [Y-~*P]ATP (5 @M, 1 
&Ci/assay) and MgClz (5 mM) were added to aliquots 
of cytosol, plasma membranes, or nuclei alone or in 
combination with 1 hug of FGF-2 as substrate. After a 
15 min incubation at room temperature, the reaction 
was tetrad by the addition of Laemmli’s sample 
buffer, and the phosphorylated proteins were analyzed 
by SDS-PAGE and autoradiography. Total protein was 
visualized by Coomassie blue staining. As shown in Fig. 
2 at the concentration tested, the cytosolic fraction of 
SK-Hep-1 cells contains no detectable FGF-2 kinase 
activity, while the plasma membranes and nuclei prepa- 
rations of SK-Hep-1 cells (Fig. 2B) have a si~~cant 
ability to phosphorylate FGF-2. The reaction is partic- 
ularly impressive in nuclei, since so little protein is pres- 
ent in the reaction (Fig. ZA). Identical incubations with 
subcellular fractions of 3T3 cells reveal that these cell 
compartments contain barely detectable levels of FGF 
kinase activity (Fig. 2C,D). 
3.3. Kinetic properties of nuclear FGF-2 kinase 
Having previously described an ecto-protein kinase 
activity that is associated with the plasma membrane of 
SK-Hep-1 cells, we focused further studies on the phos- 
phorylation of FGF-2 by nuclear protein kinase(s). The 
kinetic properties of the enzyme were examined by mod- 
ifying the effects of time, concentration of enzyme (nu- 
clei), and substrate. When the number of purified nuclei 
is increased from 2,500fml to 85,000 nuclei/ml, there is 
a dose-dependent increase in the phosphorylation of 
FGF-2 (Fig. 3A). The reaction is time dependent, and 
the incorporation of phosphate into FGF-2 is linear for 
10 min at 22”C, with up to l~,~O nuclei/ml (Fig. 3B). 
The substrate specificity of the nuclear kinase was deter- 
mined using histone H2A, casein, and FGF-2 as ex- 
ogenous substrates. The enzyme preparation preferen- 
tially phosphorylates FGF-2 -+ casein -+ histone (not 
shown), and Lineweaver-Burke analyses of the dose 
curves approx~ate an apparent Km of 0.18 FM. This 
value is well within the expected range for a potentially 
physiological substrate. In these crude preparations of 
enzyme however, the stoic~omet~ is low (~0.3 mol 
phosphate/m01 FGF-2) but increases with purification 
(unpublished observations). Phosphoamino acid analy- 
ses reveal that the enzyme targets serine, thus classifying 
the enzyme as a serine kinase (not shown). Mapping of 
this site is in progress. 
3.4. characterization of the pho~phorylatio~ of FGF-2 
by purij?ed nuclei 
Our initial attempts to characterize the phosphoryla- 
tion of FGF-2 by purified nuclei are presented in Table 
I. ne presence of ma~esi~ is required for nuclei to 
phosphorylate FGF-2. While this activity is increased 
by concentrations of Me below 10 mM, higher con- 
~ntrations are inhibitor. For this reason, all subse- 
quent assays for the enzyme were performed in the pres- 
ence of 5 mM Mg2’. Ca*’ cannot substitute for Me, 
and there is no additive effect when both ions are pres- 
ent in the assay buf%er. Agents that modulate the activ- 
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Fig. 1. Localization of FGF-2 in SK-Hep-l-l cells. Cells were grown in culture as described in the text, and the presence of FGF-2 established 
by immunohistochemistry of nonpermeabilized (Panel A) and permeabilixed (Panel B) cells. The antigens recognized are the forms of FGF-2s that 
are expected as determined by Western blotting of the extracts without (1) or with (2) adsorption and elution from heparin-Sepharose (Panel C). 
The molecular weight markers (x10-‘) and mobility of FGF-2 are indicated. 
ities of protein kinase A (PK-A) or protein kinase C concentrations of spermidine or heparin, there is a dose- 
(PK-C) have no effect on the phosphorylation of FGF-2 dependent inhibition of phosphorylation of FGF-2 by 
by the protein kinase. Neither CAMP, the heat- and the purified nuclei. Under the assay conditions used 
acid-stable PK-A inhibitory protein PK-I, phorbol es- here, spermidine had an IC,,, of 3 mM, while heparin 
ters, or a mixture of phosphoatidyl serine/dolein inhibits at 1 pg/rnl. Accordingly, the reaction appears 
changes the phosphorylation pattern of FGF-2. When to be sensitive to an effect of glycosaminoglycans and 
the assays are performed in the presence of increasing polyamines which are presumably acting either on 
SK&p-l 
(A) (B) 
Balb 3T3 
(c) (W 
Fig. 2. Subcellular localixation of FGF-2 kinase in SK-Hep-1 and Balb-C 3T3 cells. Subcellular fractions from SK-Hep-1 (A,B) and Balb-C 3T3 
cells (C,D) were obtained as described in section 2. An aliquot of each fraction (15 ~1) was incubated with (+) or without FGF-2 (1 @ml) and 
[7-32P]ATP for 20 mm at room temperature. The reaction was stopped by addition of a 5x solution of Laemmli sample buffer (5 ~1). Proteins were 
analyzed by SDS-PAGE and visualized by Coomassie blue staining of the gels (Panels A and C), and the extent of phosphorylation by autoradi- 
ography (Panels B and D). The mobility of FGF-2 is indicated. 
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Fig. 3. Kinetics of the phosphorylation f FGF-2 by the puri&d nuclei 
of SK-Hap-1 cells. FGF-2 (500 ngltube) was ph~ho~iat~ by in- 
creasing inundations of nuclei (Panel 3A) as described in the text, 
and the radioiabelled FGF-2 examined by autoradiography after 
SDS-PAGE. The FGF-2 shown in the inset were cut from the gel and 
counted on a B-counter to yield the data shown in the graph. The 
phosphorylation assay was also performed with a fixed number of 
nuclei, but stopped at different times (Panel B). The bands in Lanes 
1 through 6 correspond to incubations topped at the indicated times, 
respectively. The FGF-2 shown in the inset were cut from the gel and 
counted on a p-counter to yield the data shown in the graph. 
FGF-2 itself to prevent its association with the nucleus, 
its interaction with the kinase, or by interacting with the 
kinase directly. Each of these possibilities is currently 
being investigated with the purified enzyme. 
4. DISCUSSION 
The findings presented here demonstrate the exis- 
tence of protein kinases distinct from wither PKC or 
PKA which can phosphorylate FGF-2. They are pres- 
ent in the plasma membranes and nuclei of proliferating 
SK-Hep-1 cells. Only a small component of these activ- 
ities might be attributable to the presence of the known 
kinases that can phosphorylate FGF-2 like PK-C or 
PK-A [29,30], because the major activity in each com- 
partment appears distinct. In previous studies [17,26], 
we characterized amembrane-bound ectoprotein kinase 
that phosphorylates FGF-2, and we presume the activi- 
ties detected here in the plasma membrane preparations 
are due to this same enzyme. The nuclear kinase activ- 
ity, however, appears novel. It is not CAMP, phospho- 
lipid, and calcium dependent (manuscript in prepara- 
tion), and is barely detectable in proliferating Balb-C 
3T3 cells. Balb-C 3T3 is a cell type which has no en- 
dogenous FGF-2, but responds well to the growth fac- 
tor. 
Human hepatoma SK-Hep-1 cells synthesize large 
quantities of FGF-2 and possess high atlinity receptors, 
yet respond poorly to exogenous FGF-2. Although its 
intracellular localization is essentially nuclear, the pos- 
sible role (if any) of FGF-2 phospho~lation in the nu- 
cleus is not known. For several years now, the impor- 
tance of phosphorylation in the activation of DNA- 
binding proteins has been described for transcription 
factors. In view of FGF-2 being localized in this com- 
partment, it may be worth considering the possibility 
that it is itself a transcription factor and/or a cis- or 
trans-acting element regulated by phosphorylation. 
Thus FGF-2 resembles c-+&s [3 I], CREs 1321, and serum 
responsive lements [33] to the extent it localizes to the 
nucleus [27], is phosphorylated [29,30], and its subcellu- 
lar distribution appears linked to the cell cycle, cell 
growth, and differentiation [27,39]. Of course, the phos- 
phorylation of FGF-2 could also play a role in its traf- 
ficking through different compartments of the cell [36- 
38]. Accordingly, it is particularly interesting to note the 
abundance of the nuclear FGF-2 kinase activity in the 
Table I 
Characterization of the phosphorylation of FGF-2 by purified nuclei 
Treatment 
MgCi, (mW 
Control 
CaC12 
CAMP 
CAMP + PKI 
Heparin @g/ml) 
Spermidine (mM) 
Concentration [‘2P]FGF (cpm) 
0.3 56 
2.0 294 
5.0 322 
10.0 634 
50.0 297 
(+lO mM MgCl,) 608 
0.45 mM 549 
3.5 mM 511 
3.5 PM 622 
0.0 608 
0.4 469 
0.8 414 
3.2 142 
12.5 17 
31.2 18 
0.0 622 
0.37 519 
0.73 498 
1.46 684 
2.90 419 
5.85 420 
11.70 220 
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cells which have endogenous FGF (SK-Hep-1 cells), 
compared those that do not (Balb-C 3T3 cells). 
Finally, it is important to highlight the potent inhib- 
itory effects of both heparin and spermidine on the 
phosphorylation of FGF-2 by nuclei. Both molecules 
belong to families which have critically important roles 
in the control of normal cell growth and function. For 
example, heparin can potently suppress the entry of cells 
into S-phase in response to mitogens by arresting them 
early in the cell cycle, and can selectively inhibit the 
mitogenic stimulation of cells by TPA and serum. Pol- 
yamines as well have long been associated with cell 
proliferation and differentiation. In view of the striking 
effects of both heparin and spermidine on the phospho- 
rylation of FGF-2 by the purified nuclei, it is interesting 
to speculate that these agents might also regulate FGF- 
2’s phosphorylation in vivo. If so, a trophic stimulus 
modulating the intracellular levels of GAGS and pol- 
yamines would, in turn, modulate the nuclear FGF-2 
phosphorylation. Whether this effect is directly on the 
kinase or mediated through other components of the 
nuclei (e.g., transport), these observations further sup- 
port a potential role for FGF-2 phosphorylation in the 
regulation of cell growth and function. 
Acknowledgements: The authors wish to thank Emelie Amburn for her 
technical assistance, P. Sarmientos for the recombinant FGF-2, and 
Denise Higgins and Annemarie Putze Reid for preparation of the 
manuscript. Research was supported by the National Institutes of 
Health Grant DK18811, and the Whittier-Erbamont Angiogenesis 
Research Program. I.V. was a Visiting Scientist from INSERM Unite 
244, Grenoble France, and a Fellow of the Human Science Frontier 
Organization. 
REFERENCES 
[l] Baird, A. and Klagsbrun, M. (1991) Ann. NY Acad. Sci. 638, 
xi-xii. 
[2] Gospodarowicz, D., Ferrara, N., Schweigerer, L. and Neufeld, 
G. (1987) Endocrinol. Rev. 8, 95-l 14. 
[3] Schweigerer, L., Neufeld, G., Friedman, J., Abraham, J.A., Fid- 
des, J.C. and Gospodarowicz, D. (1987) Nature 325, 257-259. 
[4] Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai- 
Michaeli, R., Sasse, J. and Klagsbrun, M. (1987) Proc. Natl. 
Acad. Sci. USA 84, 2292-2296. 
[5] Neufeld, G., Ferrara, N., Schweigerer, L., Mitchell, R. and 
Gospodarowicz, D. (1987) Endocrinology 121, 597-603. 
[6] Halaban, R., Kwon, B., Ghosh, S., Delli Bovi, P. and Baird, A. 
(1988) Mol. Cell. Biol. 8, 2933-2941. 
[7] Schweigerer, L., Neufeld, G., Mergia, A., Abraham, J.A., Fiddes, 
J.C. and Gospodarowicz, D. (1987) Proc. Natl. Acad. Sci. USA 
84, 842-846. 
[8] Becker, D., Meier, C.B. and Herlyn, M. (1989) EMBO J. 8, 
3685-369 1. 
[9] Abraham, J.A., Mergia, A., Whang, J.L., Tumolo, A., Friedman, 
J., Hjerrield, K.A., Gospodarowicz, D. and Fiddes, J.C. (1986) 
Science 233, 545-548. 
[lo] Florkiewicz, R.Z., Baird, A. and Gonzalez, A.-M. (1991) Growth 
Factors 4, 265-275. 
[ll] Baird, A. and Ling, N. (1987) Biochem. Biophys. Res. Commun. 
142,428435. 
[12] Kardami, E. and Fandrich, R.R. (1989) J. Cell Biol. 109, 1865- 
1875. 
[13] Powell, P.P. and Klagsbrun, M. (1991) J. Cell. Physiol. 148, 
202-210. 
[14] Tessler, S. and Neufeld, G. (1990) J. Cell. Physiol. 145, 310-317. 
[15] Bouche, G., Gas, N., Prats, H., Balsin, V., Tauber, J.P., Teissie, 
J. and Amahic, F. (1987) Proc. Natl. Acad. Sci. USA 84, 6770- 
6774. 
WI 
[I71 
WI 
P91 
PO1 
Pll 
PI 
v31 
v41 
v51 
WI 
v71 
WI 
~291 
[301 
1311 
1321 
1331 
[341 
1351 
[361 
[371 
[381 
[391 
Feige, J.J. and Baird, A. (1989) Proc. Natl. Acad. Sci. USA 86, 
31743178. 
Vilgrain, I. and Baird, A. (1991) Mol. Endocrinol. 5, 1003-1012. 
Klagsbrun, M. and Baird, A. (1991) Cell 67, 229-231. 
Hunter, T. (1987) Cell 50, 823-829. 
Nishizuka, Y. (1984) Nature 308, 693-698. 
Gonzalez, A.M., Buscaglia, M., Ong, M. and Baird, A. (1990) J. 
Cell Biol. 110, 753-765. 
Florkiewicz, R.Z. and Sommer, A. (1989) Proc. Natl. Acad. Sci. 
USA 86, 39783981. 
Laemmli, U.K. (1970) Nature 227, 680-685. 
Cuevas, P., Gonzalez, A.M., Carceller, F. and Baird, A. (1991) 
Circ. Res. 69, 36&369. 
Cooper, J.A., Sefton, B.M. and Hunter, T. (1983) Methods Enzy- 
mol. 99, 387402. 
Vilgrain, I. and Baird, A. (1991) Ann. NY Acad. Sci. 638, 445- 
448. 
Baldin, V., Roman, A.-M., Bose-Bierne, I., Amahic, F. and 
Bouche, G. (1990) EMBO J. 9, 1511-1517. 
Lawson, G.M., Tsai, M.-J., Tsaia, S.Y., Minghetti, PP., 
McClure, M.E. and O’Malley, B.W. (1988) Laboratory Manual 
for Hormone Action and Molecular Endocrinology (Schrader, 
W.T. and 0 ‘Malley, B.W. Eds.) Texas Medical Center, Houston, 
Texas. 
Feige, J.J. and Baird, A. (1989) Proc. Natl. Acad. Sci. USA 86, 
31743178. 
Feige, J.J., Bradley, J., Fryburg, K., Farris, J., Cousens, L. and 
Baird, A. (1989) J. Cell Biol. 109, 3105-3114. 
Roux, P., Blanchard, J.M., Femandez, A., Lamb, N., Jeanteur, 
P. and Piechaczyk, M. (1990) Cell 63, 341-351. 
Montminy, M.R. and Bilezikjian, L.M. (1987) Nature 328, 175- 
178. 
Prywes, R., Dutta, A., Cromlish, J.A. and Roeder, R.G. (1988) 
Proc. Natl. Acad. Sci. USA 85, 72067210. 
HoefIler, W.K., Kovehnan, R. and Roeder, R.G. (1988) Cell 53, 
907-920. 
Shirakawa, F. and Mizel, ST. (1989) Mol. Cell. Biol. 9, 2424 
2430. 
Yoneda, Y., Iwamoto-Sonobe, N., Yamaizumi, M. and Uchida, 
T. (1987) Exp. Cell. Res. 173, 586595. 
Goldberg, Y., Glineur, C., Gesquiere, J.C., Ricouart, A., Sap, J., 
Vennstrom, B. and Ghysdael, J. (1988) EMBO J. 7, 2425-2433. 
Pines, J. and Hunter, T. (1991) J. Cell Biol. 115, 1-17. 
Hill, D. and Logan, A. (1992) Growth Factors 7, 215-232. 
232 
